ERBB2 and breast carcinoma: Previously, we adopted duplex fluorescence-SERS (F-SERS) probes against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) of breast cancer and combined FBE and Raman spectroscopy as one detection system called FRES (fluorescence-Raman endoscopic system), which successfully illustrated its value in subcutaneous tumor implants as a proof-of-concept16.